A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)

 Juvenile Idiopathic Arthritis / Posted 5 months ago

Brief Summary
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
  • Inclusion Criteria :
    • Ages Eligible for Study: 1 Year to 18 Years (Child, Adult)
    • Sexes Eligible for Study: All
    • Accepts Healthy Volunteers: No
    • Participants must have completed a previous study of baricitinib for the treatment of JIA.
  • Exclusion Criteria :
    • Participants must not have had a permanent discontinuation of baricitinib in the prior study.
    • Participants must have not developed an allergy to baricitinib.
  • Study start date : April 5, 2019
  • Study end date : December 6, 2027
  • Principal Investigator : Athimalaipet V Vaidyanathan Ramanan (Bristol Royal Hospital for Children)
Contact details

Bristol Royal Hospital for ChildrenBristol,England,BS2 8BJ  Show Phone Number ClinicalTrials.gov@lilly.com www.uhbristol.nhs.uk

No post found